Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 15, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 87,508 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,249.5 pence per share; lowest price paid was 1,244.5 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.72% of total issued share capital and 9.55% of total voting rights).
- Shares in Issue: 5,164,452,691 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 87,508 repurchased shares. Consequently, the Company's Treasury shareholding increased to 493,224,284 shares. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase transaction compliant with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,164,452,691) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share percentage (8.72% of issued capital) for voting rights analysis.
- Note that the repurchased shares were cancelled, permanently reducing the share count.